|
Control (n=7) |
|
FS (n=7) |
|
Age, mean (range) |
73.4 |
(57-81) |
59.3 |
(35-79) |
T stage |
|
|
|
|
T1 |
1 (14%) |
|
1 (14%) |
|
T2 |
3 (43) |
|
2 (29) |
|
T3 |
2 (29) |
|
3 (43) |
|
T4 |
1 (14) |
|
1 (14) |
|
N stage |
|
|
|
|
N1 |
1 (14) |
|
1 (14) |
|
N2 |
5 (71) |
|
4 (57) |
|
N3 |
1 (14) |
|
2 (29) |
|
M Stage |
|
|
|
|
M0 |
5 (71) |
|
6 (86) |
|
M1 |
2 (29) |
|
1 (14) |
|
Stage (AJCC 7th edition) |
|
|
|
|
IIIA |
3 (43) |
|
4 (57) |
|
IIIB |
2 (29) |
|
2 (29) |
|
IV |
2 (29) |
|
1 (14) |
|
Location of primary tumor |
|
|
|
|
RUL |
5 (71) |
|
4 (57) |
|
RML |
0 |
|
1 (14) |
|
RLL |
0 |
|
1 (14) |
|
LUL |
1 (14) |
|
0 |
|
LLL |
1 (14) |
|
1 (14) |
|
Dose (cGy), median (range) |
7200 |
(7000-8000) |
7000 |
(5000-8000) |
Histology |
|
|
|
|
squamous cell carcinoma |
2 (29) |
|
3 (43) |
|
adenocarcinoma |
3 (43) |
|
2 (29) |
|
sarcomatoid carcinoma |
1 (14) |
|
1 (14) |
|
NSCLC, other |
1 (14) |
|
1 (14) |
|
Chemotherapy |
|
|
|
|
Concurrent |
1 (14) |
|
3 (43) |
|
Sequential |
5 (71) |
|
3 (43) |
|
No chemotherapy |
1 (14) |
|
1 (14) |
|
Chemotherapy Regimen |
|
|
|
|
Carboplatin and docetaxol |
3 (43) |
|
2 (29) |
|
Carboplatin and pemetrexed |
1 (14) |
|
0 |
|
Carboplatin and gemcitabine |
1 (14) |
|
1 (14) |
|
Cisplatin and docetaxol |
0 |
|
2 (29) |
|
Cisplatin and pemetrexed |
1 (14) |
|
1 (14) |
|
Pulmonary Function, mean (range) |
|
|
|
|
FEV1 (L) |
1.365 |
(1.29-1.44) |
2.815 |
(0.88-4.07) |
DLCO (%) |
61.5 |
(43-80) |
59.5 |
(39-97) |
Tobacco History |
|
|
|
|
Current smoker |
0 |
|
2 (29) |
|
Former smoker |
6 (86) |
|
5 (71) |
|
Pack-Years, median (range) |
45 |
(20-120) |
45 |
(3.5-100) |
Non-smoker |
1 (14) |
|
0 |
|
|